Omidsci
Human Anti centriole and centrosome antibody IgG ELISA kit |
|||
E01A0698-192T | BlueGene | 192 tests | EUR 1524 |
Description: A competitive ELISA for quantitative measurement of Human Anti centriole and centrosome antibody IgG in samples from blood, plasma, serum, cell culture supernatant and other biological fluids. This is a high quality ELISA kit developped for optimal performance with samples from the particular species. |
Human IgG antibody Laboratories manufactures the omidsci reagents distributed by Genprice. The Omidsci reagent is RUO (Research Use Only) to test human serum or cell culture lab samples. To purchase these products, for the MSDS, Data Sheet, protocol, storage conditions/temperature or for the concentration, please contact Midsci Inc.. Other Omidsci products are available in stock. Specificity: Omidsci Category:
True north Cryobox 15mLBlue |
||
Scientific Laboratory Supplies | PK10 | EUR 212.4 |
True north Cryobox 50mLNatural |
||
Scientific Laboratory Supplies | PK10 | EUR 210 |
True north Cryobox 50mLBlue |
||
Scientific Laboratory Supplies | PK10 | EUR 210 |
True north Cryobox1.5/2mLNatural |
||
Scientific Laboratory Supplies | PK10 | EUR 162 |
True north Cryobox1.5/2.0mLGreen |
||
Scientific Laboratory Supplies | PK10 | EUR 162 |
Human true insulin,TI ELISA Kit |
||
SunredBio | 96 tests | EUR 528 |
Description: A quantitative ELISA kit for measuring Human in samples from biological fluids. |
Human true insulin,TI ELISA Kit |
||
ChemNorm | 96T | EUR 567.6 |
Spike (B.1.1.529, Omicron Variant) Pseudotyped Lentivirus (Luc Reporter) |
|||
78348-1 | BPS Bioscience | 100 µl | EUR 900 |
Description: The pandemic coronavirus disease 2019 (COVID-19) is caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). As the first step of the viral replication, the virus attaches to the host cell surface before entering the cell. The viral Spike protein recognizes and attaches to the Angiotensin-Converting Enzyme 2 (ACE2) receptor found on the surface of type I and II pneumocytes, endothelial cells, and ciliated bronchial epithelial cells. Drugs targeting the interaction between the Spike protein of SARS-CoV-2 and ACE2 may offer protection against the viral infection. A variant called B.1.1.529 (also known as the Omicron Variant) was identified in South Africa in November of 2021. This variant has a large number of mutations that allow the virus to spread more easily and quickly than other variants.The Spike (B.1.1.529 Variant) (SARS-CoV-2) Pseudotyped Lentivirus were produced with SARS-CoV-2 B.1.1.529 Variant Spike (Genbank Accession #QHD43416.1 with B.1.1.529 mutations; see below for details) as the envelope glycoproteins instead of the commonly used VSV-G. These pseudovirions contain the firefly luciferase gene driven by a CMV promoter, therefore, the spike-mediated cell entry can be measured via luciferase activity. The Spike (B.1.1.529 Variant) (SARS-CoV-2) pseudotyped lentivirus can be used to measure the activity of neutralizing antibody against SARS-CoV-2 B.1.1.529 variant in a Biosafety Level 2 facility.The Spike Omicron pseudovirus has been validated for use with target cells ACE2-HEK293 (which overexpress ACE2; BPS Bioscience, #79951). |
Spike (B.1.1.529, Omicron Variant) Pseudotyped Lentivirus (Luc Reporter) |
|||
78348-2 | BPS Bioscience | 500 µl x 2 | EUR 4510 |
Description: The pandemic coronavirus disease 2019 (COVID-19) is caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). As the first step of the viral replication, the virus attaches to the host cell surface before entering the cell. The viral Spike protein recognizes and attaches to the Angiotensin-Converting Enzyme 2 (ACE2) receptor found on the surface of type I and II pneumocytes, endothelial cells, and ciliated bronchial epithelial cells. Drugs targeting the interaction between the Spike protein of SARS-CoV-2 and ACE2 may offer protection against the viral infection. A variant called B.1.1.529 (also known as the Omicron Variant) was identified in South Africa in November of 2021. This variant has a large number of mutations that allow the virus to spread more easily and quickly than other variants.The Spike (B.1.1.529 Variant) (SARS-CoV-2) Pseudotyped Lentivirus were produced with SARS-CoV-2 B.1.1.529 Variant Spike (Genbank Accession #QHD43416.1 with B.1.1.529 mutations; see below for details) as the envelope glycoproteins instead of the commonly used VSV-G. These pseudovirions contain the firefly luciferase gene driven by a CMV promoter, therefore, the spike-mediated cell entry can be measured via luciferase activity. The Spike (B.1.1.529 Variant) (SARS-CoV-2) pseudotyped lentivirus can be used to measure the activity of neutralizing antibody against SARS-CoV-2 B.1.1.529 variant in a Biosafety Level 2 facility.The Spike Omicron pseudovirus has been validated for use with target cells ACE2-HEK293 (which overexpress ACE2; BPS Bioscience, #79951). |
Nucleocapsid Protein (B.1.1.529, Omicron Variant), Avi-His-Tag (SARS-CoV-2) |
|||
101319-1 | BPS Bioscience | 100 µg | EUR 335 |
Description: Recombinant SARS-CoV-2 Nucleocapsid Protein (also known as N protein), full length encompassing amino acids 1-419 (end). This protein corresponds to SARS-CoV-2 variant B.1.1.529 (Omicron Variant), originally discovered in South Africa, and contains mutations P13L, R203K and G204R. The construct also contains a C-terminal Avi-Tag™ followed by a His-tag (6xHis). The recombinant protein was affinity purified. |
Nucleocapsid Protein (B.1.1.529, Omicron Variant), Avi-His-Tag (SARS-CoV-2) |
|||
101319-2 | BPS Bioscience | 1 mg | EUR 2730 |
Description: Recombinant SARS-CoV-2 Nucleocapsid Protein (also known as N protein), full length encompassing amino acids 1-419 (end). This protein corresponds to SARS-CoV-2 variant B.1.1.529 (Omicron Variant), originally discovered in South Africa, and contains mutations P13L, R203K and G204R. The construct also contains a C-terminal Avi-Tag™ followed by a His-tag (6xHis). The recombinant protein was affinity purified. |
Omipalisib |
|||
HY-10297 | MedChemExpress | 50mg | EUR 753.6 |
OMI / HtrA2 Peptide |
|||
3051P | ProSci | 0.05 mg | EUR 197.7 |
Description: (C2) OMI / HtrA2 peptide |
HTRA2/Omi antibody |
|||
10R-1022 | Fitzgerald | 100 ul | EUR 379.2 |
Description: Mouse monoclonal HtrA2/Omi antibody |
HtrA2/Omi Antibody |
|||
3497-100 | Biovision | each | EUR 405.6 |
HtrA2/Omi Antibody |
|||
3497R-100 | Biovision | each | EUR 379.2 |
HtrA2/Omi Antibody |
|||
3497R-30T | Biovision | each | EUR 175.2 |
HtrA2/Omi Antibody |
|||
48910-100ul | SAB | 100ul | EUR 399.6 |
HtrA2/Omi Antibody |
|||
48910-50ul | SAB | 50ul | EUR 286.8 |
HtrA2 / Omi Antibody |
|||
F54030-0.1ML | NSJ Bioreagents | 0.1 ml | EUR 322.15 |
Description: Serine protease that shows proteolytic activity against a non-specific substrate beta-casein. Promotes or induces cell death either by direct binding to and inhibition of BIRC proteins (also called inhibitor of apoptosis proteins, IAPs), leading to an increase in caspase activity, or by a BIRC inhibition-independent, caspase-independent and serine protease activity-dependent mechanism. Cleaves THAP5 and promotes its degradation during apoptosis. Isoform 2 seems to be proteolytically inactive. [UniProt] |
HtrA2 / Omi Antibody |
|||
F54031-0.1ML | NSJ Bioreagents | 0.1 ml | EUR 322.15 |
Description: Serine protease that shows proteolytic activity against a non-specific substrate beta-casein. Promotes or induces cell death either by direct binding to and inhibition of BIRC proteins (also called inhibitor of apoptosis proteins, IAPs), leading to an increase in caspase activity, or by a BIRC inhibition-independent, caspase-independent and serine protease activity-dependent mechanism. Cleaves THAP5 and promotes its degradation during apoptosis. Isoform 2 seems to be proteolytically inactive. [UniProt] |
Omite 1000 ug.mL in HPLC Acetone |
|||
LCS-2895 | Scientific Laboratory Supplies | 1ML | EUR 189.6 |
HTRA2 Antibody / Omi |
|||
RQ4736 | NSJ Bioreagents | 100ul | EUR 356.15 |
Description: The HTRA2 gene encodes a serine protease. The protein has been localized in the endoplasmic reticulum and interacts with an alternatively spliced form of mitogen-activated protein kinase 14. The protein has also been localized to the mitochondria with release to the cytosol following apoptotic stimulus. The protein is thought to induce apoptosis by binding the apoptosis inhibitory protein baculoviral IAP repeat-containing 4. [RefSeq] |
Spike (B.1.1.529, Omicron Variant) (SARS-CoV-2) Pseudotyped Lentivirus (eGFP Reporter) |
|||
78349-1 | BPS Bioscience | 100 µl | EUR 875 |
Description: The pandemic coronavirus disease 2019 (COVID-19) is caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). As the first step of the viral replication, the virus attaches to the host cell surface before entering the cell. The viral Spike protein recognizes and attaches to the Angiotensin-Converting Enzyme 2 (ACE2) receptor found on the surface of type I and II pneumocytes, endothelial cells, and ciliated bronchial epithelial cells. Drugs targeting the interaction between the Spike protein of SARS-CoV-2 and ACE2 may offer protection against the viral infection. A variant called B.1.1.529 (also known as the Omicron Variant) was identified in South Africa in November of 2021. This variant has a large number of mutations that allow the virus to spread more easily and quickly than other variants.The Spike (B.1.1.529 Variant) (SARS-CoV-2) Pseudotyped Lentiviruses were produced with SARS-CoV-2 B.1.1.529 Variant Spike (Genbank Accession #QHD43416.1 with B.1.1.529 mutations; see below for details) as the envelope glycoproteins instead of the commonly used VSV-G. These pseudovirions contain the eGFP gene driven by a CMV promoter, therefore, the spike-mediated cell entry can be determined via eGFP fluorescence. The Spike (B.1.1.529 Variant) (SARS-CoV-2) pseudotyped lentivirus can be used to measure the activity of neutralizing antibody against SARS-CoV-2 B.1.1.529 variant in a Biosafety Level 2 facility.The Spike Omicron pseudovirus has been validated for use with target cells ACE2-HEK293 (which overexpress ACE2; BPS Bioscience, #79951).Spike Mutations in B.1.1.529 Variant:A67V, Δ69-70, T95I, G142D, Δ143-145, Δ211, L212I, ins214EPE, G339D, S371L, S373P, S375F, K417N, N440K, G446S, S477N, T478K, E484A, Q493R, G496S, Q498R, N501Y, Y505H, T547K, D614G, H655Y, N679K, P681H, N764K, D796Y, N856K, Q954H, N969K, L981F |